'The Global Market for Needle-Free Injection Devices Will be Worth $4.49bn by 2022' Predicts visiongain Research

Informations

• Publié par: visiongain
• Nombre de lectures: 19
• Langue: English

Extrait

'The Global Market for Needle-Free Injection Devices Will be Worth $4.49bn by 2022' Predicts visiongain Research

PR Newswire LONDON, September 14, 2012

LONDON,September 14, 2012/PRNewswire/ -- A new report by visiongain, aLondon-based business information provider, predicts that the global market for Needle-Free Injection Devices will be worth $4.49bnby 2022. The market generated sales of$1.09bnin 2011. The delivery of medicine and drugs to patients is typically though the use of pills, tablets or even in liquid form. In some cases when the drug needs to reach the systemic circulation quicker, or when the drug has a shorter half life, often seen during emergencies, the drug will be administered by injection, for example, intravenously (i.v.). Indeed, there are large numbers of therapies, particularly protein-, gene- and vaccine-based medications that cannot be delivered orally. In recent years however, there has been growing concern over the use of needle-based injections. Much of this concern is psychologically- based where patients suffer from a phobia of needles. This has been particularly documented across large demographic groups, such as diabetics. One such alternative, which is growing in popularity and has received considerable attention during the past few years (especially as the safety and efficacy of needle/syringe delivery has been questioned) is Needle-Free Injection (NFI) technology. Visiongain's healthcare industry analyst, says "While drug pills and tablets have been the most widely accepted form of drug delivery, in recent years there has been a shift away from these traditional methods and towards specialised delivery systems that can provide safer and more effective methods of medication. A needle free injection device is one example of an innovative system that has addressed patient concerns regarding the risk of needle infections, frequency of injections and painful drug administration. Due to high start up and maintenance costs, the initial adoption of needle-free systems was slow. However, with the introduction of devices that are now designed to work with existing drug formulations, development costs have been reduced. This has accelerated the adoption of needle-free injection devices, indicated for a wide variety of administrations including vaccines, hormones and anaesthetics". Visiongain's report; Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2012-2022,also suggests that the world needle free injection device market will also benefit from a large number of leading drugs losing patent, which offers opportunity for companies in the needle-free delivery market to develop novel devices for their delivery. This helps pharmaceutical companies manage the life cycle of their drugs and allows for patent extensions. Visiongain predicts that this market will grow steadily to 2022. The future of needle free injection systems appears promising and has significant potential for growth owing to the increasing demand for safer, less painful methods of drug administration. This new report adds to visiongain's wide range of

analytical reports in healthcare and other industry areas. For further information concerning the Visiongain'sMedical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2012-2022please visit http://www.visiongain.com/Report/893/Medical-Device-Leader-Series-Top- Needle-Free-Injection-Device-Manufacturers-2012-2022 Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to [e-mail] or call her on [phone] About visiongain Visiongain is one of the fastest growing and most innovative independent media companies inEurope. Based inLondon, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e- zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors. visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of- call for the business professional, who needs independent, high quality, original material to rely and depend on. Companies Listed in the report include: Activa (Advantajet) Akra Dermojet Antares Pharma Astellas Pharma AstraZeneca Battelle Bioject Medical Technologies BioValve Technologies Bristol-Myers Squibb Covidien Crossject Medical technology D'Antonio Consultants International Diabetes Management International Dr. Reddy's Laboratories Durect Echo Therapeutics Eli Lilly & Co Eurojet Medical Ferndale Pharma Group Ferring Pharmaceuticals Glide Pharma GlaxoSmithKline (GSK) JCR Pharmaceuticals Mallinckrodt Medical International Technologies Merck Serono MGlas AG Minnesota Rubber and Plastics (MRP) MPI Research National Medical Products Nektar Therapeutics

Nova Nordisk Novartis Nypro Limited Patheon Penjet Corporation Pfizer PharmaJet Sanofi-Pasteur Takeda Teva Pharmaceuticals Valeritas Zogenix

Government Agencies and Other Organisations Mentioned in This Report FDA WHO UN CDRH EU USAMRIID PATH CDC Contact: Email: Sara Peerun on [e-mail] Tel: [phone]